Quantcast
Last updated on April 24, 2014 at 11:50 EDT

Latest macular hole Stories

2014-02-20 16:26:52

WEST CONSHOHOCKEN, Pa., Feb. 20, 2014 /PRNewswire-USNewswire/ --The Macula Vision Research Foundation (MVRF) will host a FREE SupportSight(SM) seminar on February 25, 2014 about the latest in research, treatment, patient care and early detection, technology and coping with vision impairment. WHO: MVRF - a national nonprofit focused on finding a cure for macular degeneration and other retinal diseases. To reach this goal, MVRF funds groundbreaking research projects conducted by...

2013-11-20 16:26:25

LEUVEN, Belgium, November 20, 2013 /PRNewswire/ -- Canada is the first market launch for JETREA(R) outside the US and Europe ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R) (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA) in Canada. Canada is the first market where...

2013-11-20 12:28:03

-- First and only eye medicine to treat sight-threatening, symptomatic vitreomacular adhesion affecting 15,000 Canadians each year MISSISSAUGA, ON, Nov. 20, 2013 /CNW/ - Alcon, the global leader in eye care and a division of Novartis, announced today that JETREA(® )(ocriplasmin) solution for intravitreal injection is now available to Canadians who suffer from symptomatic vitreomacular adhesion.(1,2 )Vitreomacular adhesion, or VMA, is an...

2013-10-22 20:21:33

LEUVEN, Belgium, October 23, 2013 /PRNewswire/ -- Final guidance confirms metamorphopsia, an early symptom of VMT, as severe and distressing, requiring early treatment - NICE final guidance recommends reimbursement of JETREA for treatment of a broad range of VMT patients, from early stage to late-stage: patients with epiretinal membranes (ERMs) are excluded - NICE recommends reimbursement for...

2013-10-21 04:20:59

LEUVEN, Belgium, October 21, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that JETREA(R) (ocriplasmin) is nominated for the 2013 Prix Galien USA Award in the Best Biotechnology Product category. The Prix Galien USA, now in its seventh year, is an international award that recognizes outstanding achievements in improving human health...

2013-10-17 16:25:13

LEUVEN, Belgium, October 17, 2013 /PRNewswire/ -- Decision confirms therapeutic benefits for treatment of VMT patients suffering from mild and moderate symptoms, or 94% of the indicated VMT population ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the Final Early Benefit Assessment from the German Federal Joint Committee (G-BA) has...

2013-10-01 12:31:06

LEUVEN, Belgium, October 1, 2013 /PRNewswire/ -- Largest ever retrospective review of VMA/VMT patients confirms early treatment initiation may stop disease progression and lead to better visual function outcome - Retrospective review of patients presenting with vitreomacular adhesion (VMA), vitreomacular traction (VMT), macular hole (MH) with/ without VMA, with or without visual...

2013-09-02 12:20:43

LEUVEN, Belgium, September 2, 2013 /PRNewswire/ -- Metamorphopsia confirmed as a severe and distressing symptom deserving immediate attention and early treatment with reimbursement - NICE FAD recommending reimbursement of JETREA for treatment of VMT patients, from early stage to late-stage (full thickness macular hole (FTMH) < 400 microns), when severe and distressing symptoms; patients with ERMs are...

2013-08-29 16:24:27

LEUVEN, Belgium, August 29, 2013 /PRNewswire/ -- Conference call and webcast scheduled today at 06:30 PM CET - 12:30 PM EST - Total H1 2013 revenue amounted to EUR102.7 million - Profitable first half - net profit of EUR54.6 million - End of June 2013 cash position of EUR193.6 million - JETREA(R) launched in the US in mid-January: initial US sales H1 2013 (end of June) amounted to EUR12.5 million ($US 16.6 million)...

2013-08-16 12:24:24

LEUVEN, Belgium, August 16, 2013 /PRNewswire/ -- Canada is first market outside the US and Europe where JETREA(R) is approved ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Health Canada has approved JETREA(R) (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). The priority review of the New Drug Submission for...